Neurocrine Biosciences, Inc. (0K6R.L)
USD 138.27
(1.59%)
USD 138.27
(1.59%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.59 Billion USD | 19.41% |
| 2022 | 1.21 Billion USD | 33.48% |
| 2021 | 911.4 Million USD | 28.67% |
| 2020 | 708.3 Million USD | 27.83% |
| 2019 | 554.1 Million USD | 35.33% |
| 2018 | 409.45 Million USD | 40.35% |
| 2017 | 291.73 Million USD | 79.67% |
| 2016 | 162.37 Million USD | 42.47% |
| 2015 | 113.97 Million USD | 76.94% |
| 2014 | 64.41 Million USD | 22.46% |
| 2013 | 52.59 Million USD | 1.75% |
| 2012 | 51.69 Million USD | 19.08% |
| 2011 | 43.4 Million USD | -8.08% |
| 2010 | 47.22 Million USD | -6.75% |
| 2009 | 50.63 Million USD | -44.52% |
| 2008 | 91.27 Million USD | -57.24% |
| 2007 | 213.46 Million USD | 39.93% |
| 2006 | 152.55 Million USD | 2.41% |
| 2005 | 148.96 Million USD | 8.33% |
| 2004 | 137.51 Million USD | -30.5% |
| 2003 | 197.86 Million USD | 62.64% |
| 2002 | 121.66 Million USD | 42.92% |
| 2001 | 85.12 Million USD | 62.49% |
| 2000 | 52.38 Million USD | 35.02% |
| 1999 | 38.8 Million USD | 28.9% |
| 1998 | 30.1 Million USD | 11.9% |
| 1997 | 26.9 Million USD | 55.49% |
| 1996 | 17.3 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 429.3 Million USD | 0.84% |
| 2024 Q1 | 397.2 Million USD | 11.45% |
| 2024 Q2 | 426.7 Million USD | 7.43% |
| 2023 Q2 | 367.6 Million USD | -3.82% |
| 2023 FY | 1.45 Billion USD | 19.41% |
| 2023 Q1 | 382.2 Million USD | 27.02% |
| 2023 Q4 | 356.4 Million USD | 2.89% |
| 2023 Q3 | 346.4 Million USD | -5.77% |
| 2022 Q1 | 302.9 Million USD | 24.19% |
| 2022 Q4 | 300.9 Million USD | 2.35% |
| 2022 Q3 | 294 Million USD | -7.75% |
| 2022 Q2 | 318.7 Million USD | 5.22% |
| 2022 FY | 1.21 Billion USD | 33.48% |
| 2021 Q3 | 247.3 Million USD | 13.44% |
| 2021 Q4 | 243.9 Million USD | -1.37% |
| 2021 Q2 | 218 Million USD | 7.81% |
| 2021 FY | 911.4 Million USD | 28.67% |
| 2021 Q1 | 202.2 Million USD | 16.74% |
| 2020 Q2 | 177.4 Million USD | 0.74% |
| 2020 FY | 708.3 Million USD | 27.83% |
| 2020 Q3 | 181.6 Million USD | 2.37% |
| 2020 Q4 | 173.2 Million USD | -4.63% |
| 2020 Q1 | 176.1 Million USD | 12.45% |
| 2019 FY | 554.1 Million USD | 35.33% |
| 2019 Q2 | 142.51 Million USD | 13.84% |
| 2019 Q3 | 129.76 Million USD | -8.94% |
| 2019 Q4 | 156.6 Million USD | 20.68% |
| 2019 Q1 | 125.19 Million USD | 15.82% |
| 2018 Q4 | 108.08 Million USD | 12.73% |
| 2018 Q2 | 97.9 Million USD | -9.0% |
| 2018 Q1 | 107.58 Million USD | 31.32% |
| 2018 FY | 409.45 Million USD | 40.35% |
| 2018 Q3 | 95.88 Million USD | -2.06% |
| 2017 Q1 | 79.93 Million USD | 72.82% |
| 2017 Q3 | 66.33 Million USD | 4.4% |
| 2017 FY | 291.73 Million USD | 79.67% |
| 2017 Q4 | 81.92 Million USD | 23.5% |
| 2017 Q2 | 63.54 Million USD | -20.5% |
| 2016 FY | 162.37 Million USD | 42.47% |
| 2016 Q2 | 41.82 Million USD | 16.65% |
| 2016 Q3 | 38.43 Million USD | -8.11% |
| 2016 Q4 | 46.25 Million USD | 20.33% |
| 2016 Q1 | 35.85 Million USD | 16.62% |
| 2015 Q2 | 25.32 Million USD | 14.8% |
| 2015 Q3 | 35.84 Million USD | 41.55% |
| 2015 Q4 | 30.74 Million USD | -14.22% |
| 2015 Q1 | 22.05 Million USD | 7.76% |
| 2015 FY | 113.97 Million USD | 76.94% |
| 2014 Q3 | 16.85 Million USD | 17.38% |
| 2014 Q4 | 20.46 Million USD | 21.42% |
| 2014 Q2 | 14.36 Million USD | 12.86% |
| 2014 FY | 64.41 Million USD | 22.46% |
| 2014 Q1 | 12.72 Million USD | 3.79% |
| 2013 Q1 | 13.7 Million USD | 2.54% |
| 2013 FY | 52.59 Million USD | 1.75% |
| 2013 Q4 | 12.26 Million USD | -3.73% |
| 2013 Q3 | 12.73 Million USD | -8.36% |
| 2013 Q2 | 13.89 Million USD | 1.4% |
| 2012 Q3 | 13.31 Million USD | 11.47% |
| 2012 Q4 | 13.36 Million USD | 0.35% |
| 2012 FY | 51.69 Million USD | 19.08% |
| 2012 Q1 | 13.05 Million USD | 22.47% |
| 2012 Q2 | 11.94 Million USD | -8.5% |
| 2011 Q2 | 10.98 Million USD | 3.9% |
| 2011 Q4 | 10.66 Million USD | -5.48% |
| 2011 FY | 43.4 Million USD | -8.08% |
| 2011 Q3 | 11.28 Million USD | 2.69% |
| 2011 Q1 | 10.57 Million USD | -25.47% |
| 2010 Q3 | 11.86 Million USD | 14.07% |
| 2010 Q2 | 10.39 Million USD | -3.49% |
| 2010 Q1 | 10.77 Million USD | 12.31% |
| 2010 FY | 47.22 Million USD | -6.75% |
| 2010 Q4 | 14.18 Million USD | 19.6% |
| 2009 Q4 | 9.59 Million USD | -7.46% |
| 2009 Q3 | 10.36 Million USD | -33.69% |
| 2009 FY | 50.63 Million USD | -44.52% |
| 2009 Q1 | 15.04 Million USD | -52.16% |
| 2009 Q2 | 15.63 Million USD | 3.94% |
| 2008 Q1 | 22.51 Million USD | -82.57% |
| 2008 Q2 | 20.85 Million USD | -7.38% |
| 2008 Q3 | 16.46 Million USD | -21.03% |
| 2008 FY | 91.27 Million USD | -57.24% |
| 2008 Q4 | 31.44 Million USD | 90.97% |
| 2007 FY | 213.46 Million USD | 39.93% |
| 2007 Q4 | 129.12 Million USD | 339.71% |
| 2007 Q3 | 29.36 Million USD | 6.41% |
| 2007 Q2 | 27.59 Million USD | 0.8% |
| 2007 Q1 | 27.37 Million USD | 6.52% |
| 2006 Q4 | 25.7 Million USD | -37.72% |
| 2006 Q1 | 47.07 Million USD | 21.61% |
| 2006 FY | 152.55 Million USD | 2.41% |
| 2006 Q3 | 41.27 Million USD | 7.17% |
| 2006 Q2 | 38.5 Million USD | -18.19% |
| 2005 Q1 | 31.21 Million USD | -21.32% |
| 2005 FY | 148.96 Million USD | 8.33% |
| 2005 Q2 | 39.42 Million USD | 26.3% |
| 2005 Q3 | 39.62 Million USD | 0.51% |
| 2005 Q4 | 38.7 Million USD | -2.32% |
| 2004 Q4 | 39.66 Million USD | 5.13% |
| 2004 Q3 | 37.73 Million USD | 32.68% |
| 2004 Q2 | 28.43 Million USD | -10.21% |
| 2004 Q1 | 31.67 Million USD | -28.84% |
| 2004 FY | 137.51 Million USD | -30.5% |
| 2003 FY | 197.86 Million USD | 62.64% |
| 2003 Q4 | 44.5 Million USD | 3.91% |
| 2003 Q3 | 42.83 Million USD | -25.45% |
| 2003 Q2 | 57.45 Million USD | 8.27% |
| 2003 Q1 | 53.06 Million USD | 17.53% |
| 2002 FY | 121.66 Million USD | 42.92% |
| 2002 Q4 | 45.15 Million USD | 64.28% |
| 2002 Q1 | 22.77 Million USD | -19.33% |
| 2002 Q2 | 26.24 Million USD | 15.23% |
| 2002 Q3 | 27.48 Million USD | 4.71% |
| 2001 Q4 | 28.23 Million USD | 38.42% |
| 2001 Q3 | 20.4 Million USD | 7.82% |
| 2001 Q2 | 18.92 Million USD | 7.7% |
| 2001 Q1 | 17.56 Million USD | 13.81% |
| 2001 FY | 85.12 Million USD | 62.49% |
| 2000 FY | 52.38 Million USD | 35.02% |
| 2000 Q1 | 10.52 Million USD | 7.38% |
| 2000 Q3 | 15.57 Million USD | 43.41% |
| 2000 Q4 | 15.43 Million USD | -0.87% |
| 2000 Q2 | 10.85 Million USD | 3.18% |
| 1999 FY | 38.8 Million USD | 28.9% |
| 1999 Q4 | 9.8 Million USD | -8.41% |
| 1999 Q2 | 9.5 Million USD | 9.2% |
| 1999 Q1 | 8.7 Million USD | 58.18% |
| 1999 Q3 | 10.7 Million USD | 12.63% |
| 1998 Q2 | 6.6 Million USD | -4.35% |
| 1998 Q3 | 11 Million USD | 66.67% |
| 1998 Q4 | 5.5 Million USD | -50.0% |
| 1998 FY | 30.1 Million USD | 11.9% |
| 1998 Q1 | 6.9 Million USD | -12.66% |
| 1997 Q4 | 7.9 Million USD | 14.49% |
| 1997 Q1 | 5.9 Million USD | -6.35% |
| 1997 FY | 26.9 Million USD | 55.49% |
| 1997 Q3 | 6.9 Million USD | 15.0% |
| 1997 Q2 | 6 Million USD | 1.69% |
| 1996 Q2 | 4.4 Million USD | 69.23% |
| 1996 FY | 17.3 Million USD | 0.0% |
| 1996 Q1 | 2.6 Million USD | 0.0% |
| 1996 Q3 | 4 Million USD | -9.09% |
| 1996 Q4 | 6.3 Million USD | 57.5% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | -545.562% |
| Dynavax Technologies Corporation | 219.14 Million USD | -628.513% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -201.79% |
| Perrigo Company plc | 1.52 Billion USD | -4.449% |
| Illumina, Inc. | 3.81 Billion USD | 58.13% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 84.43% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -253.997% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 96.068% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 22.236% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -1223.172% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 43.292% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -3474.227% |
| Waters Corporation | 943.51 Million USD | -69.207% |
| Biogen Inc. | 5.2 Billion USD | 69.327% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -598.137% |
| Evolus, Inc. | 189.75 Million USD | -741.33% |
| Adicet Bio, Inc. | 152.03 Million USD | -950.066% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -1020.642% |
| bluebird bio, Inc. | 240.23 Million USD | -564.566% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -487.171% |
| FibroGen, Inc. | 398.11 Million USD | -301.017% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 24.515% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -11377.651% |
| Homology Medicines, Inc. | 9.87 Million USD | -16067.089% |
| Geron Corporation | 70.44 Million USD | -2166.436% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 11.309% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -273.318% |
| Myriad Genetics, Inc. | 600.1 Million USD | -166.039% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -1483.405% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -189.449% |
| Zoetis Inc. | 2.76 Billion USD | 42.26% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -3191.617% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -46.55% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 8.577% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 66.565% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -3977.593% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -104.788% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -479.086% |
| Verastem, Inc. | 92.08 Million USD | -1633.743% |
| Nektar Therapeutics | 190.9 Million USD | -736.289% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -235.146% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -13049.658% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -17.319% |
| OPKO Health, Inc. | 574.68 Million USD | -177.804% |
| Exelixis, Inc. | 1.58 Billion USD | -0.613% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -333.111% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -2763.369% |
| uniQure N.V. | 285.08 Million USD | -460.006% |
| Imunon, Inc. | 21.03 Million USD | -7491.381% |
| Blueprint Medicines Corporation | 722.86 Million USD | -120.859% |
| Insmed Incorporated | 949.26 Million USD | -68.183% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -433.379% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -290.528% |
| TG Therapeutics, Inc. | 198.47 Million USD | -704.383% |
| Incyte Corporation | 1.19 Billion USD | -34.104% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -52.921% |